Search Press releases Keywords From To 31 Aug 2023 UCB presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla[®]▼(fenfluramine) oral solution and broader epilepsies portfolio Read More 27 Jul 2023 UCB now at the inflection point – ready to start a new phase of growth Read More 18 Jul 2023 UCB Announces EU Regulatory Filing for Bimekizumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa Read More 30 Jun 2023 UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology (EAN) Meeting Read More 27 Jun 2023 UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis Read More 26 Jun 2023 UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab Read More Pagination First page Previous page Previous … Page 31 Page 32 Page 33 Page 34 Current page 35 Page 36 Page 37 Page 38 Page 39 … Page 35 of 67 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
